NIH unveils new asthma guidelines

New asthma treatment guidelines could be good news for drug companies. The government advises better day-to-day control of the disease--and that probably means more widespread use of inhaled corticosteroid drugs such as Flovent (GlaxoSmithKline), Azmacort (Sanofi-Aventis), and Pulmicort (AstraZeneca).

For patients with severe asthma, the National Institutes of Health report also recommends Omalizumab, a Genentech/Novartis drug sold under the brand name Xolair, which targets antibodies that can cause asthma symptoms.

- see the new NIH guidelines
- read the Washington Post's take
- and check out this piece on AstraZeneca's asthma drugs

Related Articles:
Scientists find link between colds and asthma attacks. Report
FDA rejects GSK's Advair for COPD. Report
NIH budget cuts cause alarm in research circles. Report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.